Drug Trial Radar · NCT04585958
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
May 21, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian cancer that remains despite treatment with a platinum treatment (platinum resistant). DS-8201a is an antibody-drug conjugate. This agent has two components: an antibody component and a chemotherapy component. The antibody component is attached to the chemotherapy molecules. Upon administration of DS-8201a, the antibody targets and binds to tumor cells that have abundant HER2 (human-epidermal growth factor receptor 2), which is a protein on the surface of some tumor cells. The chemotherapy then enters the cells and blocks deoxyribonucleic acid (DNA) replication in the tumor cells with abundant HER2, causing them to die. Olaparib is a drug that blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep tumor cells from repairing their damaged DNA, causing them to die. Giving DS-8201a and olaparib may shrink or stabilize the cancer.
Conditions
- Metastatic Malignant Solid Neoplasm
- Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma
- Unresectable Malignant Solid Neoplasm
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo CT
Echocardiography TestProcedure
Undergo echocardiography
Multigated Acquisition ScanProcedure
Undergo MUGA
OlaparibDrug
Given PO
Trastuzumab DeruxtecanBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose/recommended phase 2 doseTime frame: Up to 42 days
- Incidence of adverse eventsTime frame: Up to 30 days post treatment
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Active not recruiting
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Doral
Doral, Florida · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida · Recruiting
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.